We report two cases of meningococcal septic shock with multiple organ failure treated with prompt administration of activated protein C. This was associated with a rapid clinical improvement and early cessation of organ support. Both patients survived to hospital discharge with no long-term sequelae.
Sepsis is associated with activation of the inflammatory and coagulation pathways, whilst fibrinolysis is impaired. Multiple organ failure may develop following activation of coagulation and intravascular deposition of fibrin.
Activated protein C has anti-inflammatory, antithrombotic and pro-fibrinolytic properties. It is derived from an inactive precursor, protein C. Levels of protein C are reduced in severe sepsis, and demonstrate an inverse correlation with mortality 1 . Activated protein C has been shown to have survival benefits when administered by infusion in severe sepsis 2 . Post hoc analysis suggests that this benefit is greatest in those patients with APACHE II scores greater than 25 3 . We administered activated protein C to two patients with meningococcal septicaemia, multiple organ failure and a potentially poor prognosis. Both patients improved rapidly and were discharged from hospital with no long-term sequelae.
CASE HISTORY 1
A 39-year-old male, weight 75 kg, presented with a fourteen hour history of general malaise, fever and sore throat. He had no significant past medical history, was not taking regular prescribed medication and had no known allergies.
On examination he had widespread purpura and pyrexia of 39.7°C. He had no photophobia and a Glasgow coma score (GCS) of 15. He was peripherally cool, with heart rate 115/min, sinus rhythm, and blood pressure 90/40 mmHg. Examination was otherwise unremarkable.
Routine investigations showed a platelet count of 113 x 10 9 /l, prothrombin time (PT) 16 seconds, and activated partial thromboplastin time (APTT) 32 seconds.
Given the diagnosis of presumed meningococcal septicaemia, intravenous penicillin 2.4 g six hourly, ceftriaxone 2 g twelve hourly and dexamethasone 10 mg six hourly were prescribed. The patient remained hypotensive, requiring 3500 ml of colloid and vasoconstrictor support with noradrenaline (21 µg/minute) and vasopressin (2 units/h) within six hours of presentation. He developed respiratory failure (P a O 2 55 mmHg on high flow oxygen via a non-rebreathing mask), and received non-invasive positive pressure ventilation. He rapidly developed disseminated intravascular coagulation (platelet count 55 x 10 9 /l, PT 27 seconds, APTT 56 seconds), and was transfused four units of platelets and fresh frozen plasma (FFP) four units. Despite resuscitation he remained peripherally cool and vasoconstrictordependent, with a base deficit of 11.5 and lactate of 8.6 mmol/l. Blood cultures grew Neisseria meningitidis serogroup C. Within 12 hours of initial presentation, the patient had rapidly evolving multi-system failure due entirely to sepsis (see Table 1 ). An infusion of activated protein C was therefore prescribed at 24 µg/kg/hour for 96 hours.
His clinical condition improved rapidly. Within 27 hours of starting the activated protein C, vasoconstrictor support was stopped and the base deficit had normalized. The patient was able to sit in a chair, breathing supplemental oxygen via nasal cannulae, and tolerating a light diet. With aggressive fluid resuscitation, urine output was well maintained; serum creatinine normalized within 24 hours. Coagulation improved (Figures 1 and 2) , and no further blood products were required. He was discharged from Intensive Care after 72 hours of activated protein C infusion, and returned home with no functional deficit 10 days after hospital admission.
CASE HISTORY 2
A previously well 20-year-old male, weight 117 kg, presented with general malaise, diarrhoea and leg pain following a four day prodrome of sore throat and fever. He was taking no regular medication and had no known allergies.
On examination he had pyrexia of 38.5°C and GCS 15. He was peripherally vasoconstricted, with marked tenderness to the lower limbs. He was tachycardic (125/min) and hypotensive (blood pressure 80/40 mmHg). He was in respiratory failure (P a O 2 of 57 mmHg on high flow oxygen via a non-rebreathing mask) and was therefore intubated and ventilated before inter-hospital transfer to Intensive Care.
He was treated for generalized sepsis with ceftriaxone 2 g 12 hourly, gentamicin 240 mg bolus, clindamycin 600 mg 12 hourly, and vancomycin 1 g. Routine investigations showed creatinine 404 µmol/ litre, rhabdomyolysis with creatine kinase 2167 U/l, and coagulopathy (see Table 1 ). As he remained hypotensive and oliguric despite fluid resuscitation, inotropic and vasoconstrictor support was commenced with noradrenaline (18 µg/minute) vasopressin (5 U/h) and dobutamine (400 µg/minute). Intravenous hydrocortisone 50 mg 8 hourly was prescribed. A transthoracic echocardiogram showed a dilated left ventricle with global hypokinesis. Continuous veno-venous haemodiafiltration (CVVHDF) was started in view of his marked acidosis (pH 7.1, base deficit 16, lactate 9.4 mmol/l) and anuria. Blood cultures grew Neisseria meningitidis serogroup C, and within six hours of presentation he developed purpura fulminans. Eleven hours after initial presentation, an activated protein C infusion was prescribed at 24 µg/kg/hour for 96 hours. Within 12 hours of starting activated protein C, the noradrenaline and vasopressin infusions were weaned and discontinued. His peripheral perfusion improved markedly and the progression of the rash ceased. After 19 hours of activated protein C infusion, the inspired oxygen requirement had decreased from 0.8 to 0.35. Coagulation parameters improved (Figures 3 and 4) . A repeat echocardiogram on day 3 showed a hyperdynamic left ventricle. CVVHDF was continued for 125 hours-intravenous heparin was required at between 1000 and 1250 U/hour for the final 24 hours only. Thereafter the patient became polyuric, with a rapid fall in plasma creatinine. He returned to the ward on day 7, and went home functionally intact after 13 days.
DISCUSSION
Protein C, an endogenous plasma protein, is the inactive precursor (zymogen) of activated protein C (APC). Protein C is converted to activated protein C by binding the thrombin-thrombomodulin complex, and via another endothelial surface receptor, endothelial protein C receptor. Activated protein C has anti-thrombotic, anti-inflammatory and profibrinolytic properties, which are mediated at various points in the septic cascade. Sepsis is associated with both reduced levels of protein C and impaired conversion of protein C to activated protein C.
Plasma levels of protein C are reduced in over 80% of severely septic patients 4 , and correlate inversely with morbidity and mortality. This relationship is independent of age, illness severity, the presence of shock and the nature of the infecting organisms 1 . The low levels of protein C and haemostatic derangement persist throughout sepsis, whilst these parameters return towards normal in other, non-septic, critically ill patients 5 . In meningococcal septicaemia, low protein C levels and platelet counts are associated with purpura fulminans and increased mortality 6, 7, 8 . Septic patients demonstrate impaired conversion of protein C to activated protein C due to sepsisinduced endothelial dysfunction 4 . Decreased endothelial thrombomodulin and endothelial protein C receptor have been reported in patients with meningococcal septicaemia 9 , with possible shedding of thrombomodulin into the plasma. Therefore, activated protein C levels do not increase despite protein C infusion 9 . Anecdotal evidence, however, suggests that the use of unactivated protein C may reduce predicted morbidity and mortality in meningococcal septicaemia 8, 10, 11, 12 . These studies were uncontrolled, and patients variably received heparin 10 , haemofiltration 10, 11 , and anti-thrombin III infusion 10, 11, 12 . The PROWESS study 2 compared activated protein C with placebo in 1690 randomized patients with severe sepsis and organ dysfunction. The activated protein C group demonstrated a 6.1% absolute reduction in the risk of death. Activated protein C levels attained were equivalent to 20 times normal endogenous levels. Although the methodology of the PROWESS study has been questioned 13 , activated protein C should be considered early (within 4-12 hours) in certain clinical scenarios-purpura fulminans, toxic shock syndrome, severe community acquired pneumonia, and meningitis with multiple organ dysfunction (P-F Laterre, personal communication). There is increasing evidence to support the use of activated protein C in meningococcal septicaemia 14 old female treated with activated protein C, despite a poor prognosis as predicted by protein C level and APACHE II score. Activated protein C infusion, started 34 hours after initial presentation, was associated with normalization of coagulopathy and increased protein C activity. This patient required IPPV, CVVH and a total of 23 days in the Intensive Care Unit. Bachli et al 15 report survival in four patients with meningococcal septicaemia treated with activated protein C, with a corresponding improvement in coagulation, inflammatory markers and protein C levels. Two patients required platelet transfusions to maintain a platelet count >30 x 10 9 /l. Activated protein C was started between 8 and 24 hours after presentation; ICU stay was between 2 and 9 days.
We observed a dramatic clinical response following early administration of activated protein C to two patients with meningococcal septicaemia. This has been reported in just five cases worldwide, and never previously in Australasia. Both patients had high APACHE II scores and a high predicted risk of death. Protein C levels were not measured prior to the administrations, as the presence of purpura fulminans infers protein C deficiency 6, 7, 8 . Activated protein C was prescribed within 12 hours of initial presentation, and was associated with a marked clinical improvement, increased peripheral perfusion and reversal of coagulopathy. Inotropes and ventilatory support were weaned rapidly, and the need for intubation was averted in one case. Both patients made a good functional recovery and were discharged from hospital within two weeks. This report adds to the emerging evidence base supporting the use of activated protein C in meningococcal septicaemia with organ failure, which should be considered early in suspected cases.
